1,367 followers
1,676 followers
Our data are most relevant for women with Her-2 positive #breastca worried about cardiotoxicity. There is increasing recognition of importance of continuing treatment despite mild cardiotoxicity, even though ~10% will develop HF or worsening LV dysfunction
1,764 followers
RT @Dr_Mike_Fradley: SCHOLAR study suggests continuation of HER2 agents may be safe despite mild reduction in ejection fraction with guidan…
88 followers
RT @Dr_Mike_Fradley: SCHOLAR study suggests continuation of HER2 agents may be safe despite mild reduction in ejection fraction with guidan…
369 followers
RT @Dr_Mike_Fradley: SCHOLAR study suggests continuation of HER2 agents may be safe despite mild reduction in ejection fraction with guidan…
1,169 followers
RT @Dr_Mike_Fradley: SCHOLAR study suggests continuation of HER2 agents may be safe despite mild reduction in ejection fraction with guidan…
63,059 followers
RT @Dr_Mike_Fradley: SCHOLAR study suggests continuation of HER2 agents may be safe despite mild reduction in ejection fraction with guidan…
543 followers
Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity | JACC: CardioOncology https://t.co/oPOoGDcqvh
543 followers
RT @Dr_Mike_Fradley: SCHOLAR study suggests continuation of HER2 agents may be safe despite mild reduction in ejection fraction with guidan…
459 followers
RT @Dr_Mike_Fradley: SCHOLAR study suggests continuation of HER2 agents may be safe despite mild reduction in ejection fraction with guidan…
173 followers
RT @Dr_Mike_Fradley: SCHOLAR study suggests continuation of HER2 agents may be safe despite mild reduction in ejection fraction with guidan…
7,367 followers
RT @Dr_Mike_Fradley: SCHOLAR study suggests continuation of HER2 agents may be safe despite mild reduction in ejection fraction with guidan…
801 followers
63,059 followers
1,526 followers
RT @Dr_Mike_Fradley: SCHOLAR study suggests continuation of HER2 agents may be safe despite mild reduction in ejection fraction with guidan…
801 followers
RT @Dr_Mike_Fradley: SCHOLAR study suggests continuation of HER2 agents may be safe despite mild reduction in ejection fraction with guidan…
2,438 followers
SCHOLAR study suggests continuation of HER2 agents may be safe despite mild reduction in ejection fraction with guidance of #cardioonc clinics. #jacccardioonc @DarrylLeong #asco20 Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity https://t.co/4
4,219 followers
RT @JACCJournals: Five days remain until the release of the next issue of #JACCCardioOnc. Catch up with the most downloaded papers from the…
655 followers
RT @JACCJournals: Five days remain until the release of the next issue of #JACCCardioOnc. Catch up with the most downloaded papers from the…
16,167 followers
RT @JACCJournals: Five days remain until the release of the next issue of #JACCCardioOnc. Catch up with the most downloaded papers from the…
801 followers
RT @JACCJournals: Five days remain until the release of the next issue of #JACCCardioOnc. Catch up with the most downloaded papers from the…
105,423 followers
Five days remain until the release of the next issue of #JACCCardioOnc. Catch up with the most downloaded papers from the September issue. 2️⃣: Is trastuzumab safe for patients despite mild #cardiotoxicity? Dr. @DarrylLeong & @macdeptmed colleagues exp
4,735 followers
RT @JACCJournals: A phase I trial of #breastcancer patients receiving treatment w/ trastuzumab found that it may be safe to continue trastu…
8,097 followers
RT @JACCJournals: A phase I trial of #breastcancer patients receiving treatment w/ trastuzumab found that it may be safe to continue trastu…
629 followers
RT @JACCJournals: A phase I trial of #breastcancer patients receiving treatment w/ trastuzumab found that it may be safe to continue trastu…
58 followers
RT @JACCJournals: A phase I trial of #breastcancer patients receiving treatment w/ trastuzumab found that it may be safe to continue trastu…
224 followers
RT @JACCJournals: A phase I trial of #breastcancer patients receiving treatment w/ trastuzumab found that it may be safe to continue trastu…
4,926 followers
RT @JACCJournals: A phase I trial of #breastcancer patients receiving treatment w/ trastuzumab found that it may be safe to continue trastu…
4,596 followers
RT @onco_cardiology: Congrats @DarrylLeong. This was my favorite manuscript in the first issue of #JACCCardioOnc. Very important work. I th…
1,732 followers
RT @OncoCard_Ganken: Safety of Continuing #Trastuzumab Despite Mild Cardiotoxicity https://t.co/SBqZUOaSLy #BreastCancer #CTRCD #Cardiopro…
11,637 followers
62 followers
11,574 followers
12,517 followers
RT @OncoCard_Ganken: Safety of Continuing #Trastuzumab Despite Mild Cardiotoxicity https://t.co/SBqZUOaSLy #BreastCancer #CTRCD #Cardiopro…
972 followers
Safety of Continuing #Trastuzumab Despite Mild Cardiotoxicity https://t.co/SBqZUOaSLy #BreastCancer #CTRCD #Cardioprotection #Support HER治療ならなんとかやり切れるかも、 って思いながら心保護やってます Supporting by #CardioOnc clinic Aiming for carrying out required cancer Tx
59,918 followers
1,676 followers
RT @JACCJournals: A phase I trial of #breastcancer patients receiving treatment w/ trastuzumab found that it may be safe to continue trastu…
3,949 followers
11,574 followers
Congrats @DarrylLeong. This was my favorite manuscript in the first issue of #JACCCardioOnc. Very important work. I think your group made a good case to suggest a “keep going strategy” while GDMT for LV dysfxn if LVEF<50% in 40’s%. I would’ve love to se
534 followers
RT @JACCJournals: A phase I trial of #breastcancer patients receiving treatment w/ trastuzumab found that it may be safe to continue trastu…
629 followers
RT @JACCJournals: A phase I trial of #breastcancer patients receiving treatment w/ trastuzumab found that it may be safe to continue trastu…
4,995 followers
RT @JACCJournals: A phase I trial of #breastcancer patients receiving treatment w/ trastuzumab found that it may be safe to continue trastu…
105,423 followers
A phase I trial of #breastcancer patients receiving treatment w/ trastuzumab found that it may be safe to continue trastuzumab despite mild cardiotoxicity (#LVEF range 54-40%) with standard #heartfailure treatment. https://t.co/3pedvm13kc #JACCCardioOnc @D
1,247 followers
It may be feasible to continue trastuzumab despite mild 💔toxicity in ❤️-oncology clinic, where ACEi & beta-blockers are administered BUT ~10% may develop moderate to severe 💔failure. #jaccco Phase I Trial https://t.co/99HE2A2kKH #CardioOnc https://t.co
1,357 followers
@gatacagata26 乳がん治療の循環器イベントだと、これとかおもしろそうでした！(Twitterでちらっと見かけて気になった) 【HER開始後軽度心毒性例へのACE阻害薬・β遮断薬：第 I 相試験】 https://t.co/WWsPDn8lIv
39 followers
RT @ELS_Cardiology: Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I Trial- study sought to evaluate the safety of c…
32,533 followers
Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I Trial- study sought to evaluate the safety of continuing trastuzumab in patients with human epidermal growth factor receptor–positive breast cancer who developed mild cardiotoxicity ht
3,147 followers
32,533 followers
Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I Trial- study sought to evaluate the safety of continuing trastuzumab in patients with human epidermal growth factor receptor–positive breast cancer who developed mild cardiotoxicity ht
11,574 followers
RT @DarrylLeong: 1/ Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity https://t.co/p9Ayz7STif. Proud that this is the first pape…
2,287 followers
RT @Dr_Daniel_Cehic: Congratulations Darryl to you and your team. https://t.co/AStpafWdep
221 followers
Congratulations Darryl to you and your team.
224 followers
RT @DarrylLeong: 1/ Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity https://t.co/p9Ayz7STif. Proud that this is the first pape…
138 followers
RT @Office_j: 【HER開始後軽度心毒性例へのACE阻害薬・β遮断薬：第 I 相試験/ JACC CO】 トラスツズマブ使用下で軽度心毒性を呈した乳がん20例観察：全例ACE阻害薬・β遮断薬の少なくとも一方を服用で、90%がHER目標用量を達成。「EF<40%」で…
646 followers
Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity https://t.co/mAH17ZfvvO
1,077 followers
RT @DarrylLeong: 1/ Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity https://t.co/p9Ayz7STif. Proud that this is the first pape…
972 followers
Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity https://t.co/SBqZUOaSLy #CardioOnc #CardioJapan
1,027 followers
RT @Office_j: 【HER開始後軽度心毒性例へのACE阻害薬・β遮断薬：第 I 相試験/ JACC CO】 トラスツズマブ使用下で軽度心毒性を呈した乳がん20例観察：全例ACE阻害薬・β遮断薬の少なくとも一方を服用で、90%がHER目標用量を達成。「EF<40%」で…
1,088 followers
RT @Office_j: 【HER開始後軽度心毒性例へのACE阻害薬・β遮断薬：第 I 相試験/ JACC CO】 トラスツズマブ使用下で軽度心毒性を呈した乳がん20例観察：全例ACE阻害薬・β遮断薬の少なくとも一方を服用で、90%がHER目標用量を達成。「EF<40%」で…
599 followers
RT @MasriAhmadMD: In @JACCJournals, a nice study of 20 patients, with mildly decreased EF or EF decreased by 15% on Trastuzumab, who conti…
4,383 followers
【HER開始後軽度心毒性例へのACE阻害薬・β遮断薬：第 I 相試験/ JACC CO】 トラスツズマブ使用下で軽度心毒性を呈した乳がん20例観察：全例ACE阻害薬・β遮断薬の少なくとも一方を服用で、90%がHER目標用量を達成。「EF<40%」で中止の10%も、休薬後にEFはほぼ回復。 https://t.co/5z5sVpCMmt
3,961 followers
RT @MasriAhmadMD: In @JACCJournals, a nice study of 20 patients, with mildly decreased EF or EF decreased by 15% on Trastuzumab, who conti…
3,749 followers
Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity https://t.co/nPj9JXf9fI
2,591 followers
Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: "Approximately 10% (2/20) of patients may develop moderate to severe heart failure using this approach." https://t.co/7vwIwFCcuv https://t.co/LKxnRQFP91
8,052 followers
In @JACCJournals, a nice study of 20 patients, with mildly decreased EF or EF decreased by 15% on Trastuzumab, who continued the med, 2 out of 20 had HF with EF <40%. #ACCFIT #CardioTwitter #Cardioonc https://t.co/eCBpIxUHau https://t.co/VDvuoM1YWT
4,926 followers
534 followers
1/ Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity https://t.co/p9Ayz7STif. Proud that this is the first paper ever published in #JACC #CardioOncology - important new journal for important new specialty. @HamHealthSci @PHRIresearch @MacHealthS
96 followers
RT @PHRIresearch: .@PHRIresearch's @DarrylLeong (1st author); coauthors include PHRI's @carlycbarron, Philip Joseph, David Conen, PJ Devere…
534 followers
RT @PHRIresearch: .@PHRIresearch's @DarrylLeong (1st author); coauthors include PHRI's @carlycbarron, Philip Joseph, David Conen, PJ Devere…
4,926 followers
.@PHRIresearch's @DarrylLeong (1st author); coauthors include PHRI's @carlycbarron, Philip Joseph, David Conen, PJ Devereaux, others @McMasterU, of: Safety of Continuing #Trastuzumab Despite Mild #Cardiotoxicity: Phase I Trial https://t.co/G9dGHPikJM @JACC